Navigation Links
Zix Corporation Reports Another Record-High Revenue Quarter as Company Announces Second Quarter 2009 Financial Results
Date:7/28/2009

June 30, 2008 -------------------------------- Non-Cash Income Stock-based Tax Non-GAAP GAAP Compensation Impact ("Adjusted") Results (A) (B) Net Loss ------- ------------ ------ ------------ Revenues $6,958,000 $6,958,000 Cost of revenues 2,542,000 (78,000) 2,464,000 --------- ------- ------ --------- Gross profit 4,416,000 78,000 - 4,494,000 Operating expenses: Research and development 1,381,000 (65,000) 1,316,000 Selling, general and administrative 4,607,000 (467,000) 4,140,000 --------- --------- ------ --------- Total operating expenses 5,988,000 (532,000) - 5,456,000 --------- --------- ------ --------- Operating income/(loss) (1,572,000) 610,000 - (962,000) Other income, net 222,000 222,000 Income/(loss) before income taxes (1,350,000) 610,000 - (740,000) Provision for income taxes - (24,000) (24,000) ------------ -------- ------- ---------- Net income/(loss) $(1,350,000) $610,000 $24,000 $(716,000) =========== ======== ======= ========== Basic and diluted loss per common share $(0.02) $(0.01) Basic and diluted weighted average shares
'/>"/>
SOURCE Zix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
2. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
3. Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date
4. Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes
5. MedCath Corporation to Hold Conference Call on Third Quarter Results
6. Digirad Corporation Reports Second Quarter 2009 Financial Results
7. Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call
8. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
9. Align Technology Provides Update on Patent Litigation with Ormco Corporation
10. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
11. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release 3A August 3 2009 51439 1Varian Medical Systems Management to Present at the Piper Jaffray Cancer Summit 51436 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 2Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 3